Literature DB >> 22951600

Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study.

Tjasa Hranjec1, Laura H Rosenberger, Brian Swenson, Rosemarie Metzger, Tanya R Flohr, Amani D Politano, Lin M Riccio, Kimberley A Popovsky, Robert G Sawyer.   

Abstract

BACKGROUND: Antimicrobial treatment in critically ill patients can either be started as soon as infection is suspected or after objective data confirm an infection. We postulated that delaying antimicrobial treatment of patients with suspected infections in the surgical intensive care unit (SICU) until objective evidence of infection had been obtained would not worsen patient mortality.
METHODS: We did a 2-year, quasi-experimental, before and after observational cohort study of patients aged 18 years or older who were admitted to the SICU of the University of Virginia (Charlottesville, VA, USA). From Sept 1, 2008, to Aug 31, 2009, aggressive treatment was used: patients suspected of having an infection on the basis of clinical grounds had blood cultures sent and antimicrobial treatment started. From Sept 1, 2009, to Aug 31, 2010, a conservative strategy was used, with antimicrobial treatment started only after objective findings confirmed an infection. Our primary outcome was in-hospital mortality. Analyses were by intention to treat.
FINDINGS: Admissions to the SICU for the first and second years were 762 and 721, respectively, with 101 patients with SICU-acquired infections during the aggressive year and 100 patients during the conservative year. Compared with the aggressive approach, the conservative approach was associated with lower all-cause mortality (13/100 [13%] vs 27/101 [27%]; p=0·015), more initially appropriate therapy (158/214 [74%] vs 144/231 [62%]; p=0·0095), and a shorter mean duration of therapy (12·5 days [SD 10·7] vs 17·7 [28·1]; p=0·0080). After adjusting for age, sex, trauma involvement, acute physiology and chronic health evaluation (APACHE) II score, and site of infection, the odds ratio for the risk of mortality in the aggressive therapy group compared with the conservative therapy group was 2·5 (95% CI 1·5-4·0).
INTERPRETATION: Waiting for objective data to diagnose infection before treatment with antimicrobial drugs for suspected SICU-acquired infections does not worsen mortality and might be associated with better outcomes and use of antimicrobial drugs. FUNDING: National Institutes of Health.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22951600      PMCID: PMC3462590          DOI: 10.1016/S1473-3099(12)70151-2

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  30 in total

Review 1.  Antimicrobial resistance in the hospital setting: impact, trends, and infection control measures.

Authors:  Gary E Stein
Journal:  Pharmacotherapy       Date:  2005-10       Impact factor: 4.705

Review 2.  Clinical impact and relevance of antibiotic resistance.

Authors:  G L French
Journal:  Adv Drug Deliv Rev       Date:  2005-07-29       Impact factor: 15.470

Review 3.  Diagnosis and treatment of ventilator-associated pneumonia.

Authors:  Ilana Porzecanski; David L Bowton
Journal:  Chest       Date:  2006-08       Impact factor: 9.410

4.  Ventilator-associated pneumonia: diagnosis, treatment, and prevention.

Authors:  Steven M Koenig; Jonathon D Truwit
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

5.  Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes.

Authors:  P J Z Teixeira; R Seligman; F T Hertz; D B Cruz; J M G Fachel
Journal:  J Hosp Infect       Date:  2007-03-12       Impact factor: 3.926

Review 6.  The other fungi: it's not just Candida albicans anymore.

Authors:  Alison R Saalwachter; Traci Hedrick; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2006-04       Impact factor: 2.150

7.  Antibiotic use is associated with resistance of environmental organisms in a teaching hospital.

Authors:  S J Dancer; M Coyne; C Robertson; A Thomson; A Guleri; S Alcock
Journal:  J Hosp Infect       Date:  2005-12-01       Impact factor: 3.926

8.  Can we define the ideal duration of antibiotic therapy?

Authors:  Traci L Hedrick; Heather L Evans; Robert L Smith; Shannon T McElearney; Alison S Schulman; Tae W Chong; Timothy L Pruett; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2006-10       Impact factor: 2.150

9.  Antibiotic management of suspected nosocomial ICU-acquired infection: does prolonged empiric therapy improve outcome?

Authors:  Mary-Anne W Aarts; Christian Brun-Buisson; Deborah J Cook; Anand Kumar; Steven Opal; Graeme Rocker; Terry Smith; Jean-Louis Vincent; John C Marshall
Journal:  Intensive Care Med       Date:  2007-06-09       Impact factor: 17.440

10.  Hospital-acquired Clostridium difficile-associated disease in the intensive care unit setting: epidemiology, clinical course and outcome.

Authors:  Alexandre R Marra; Michael B Edmond; Richard P Wenzel; Gonzalo M L Bearman
Journal:  BMC Infect Dis       Date:  2007-05-21       Impact factor: 3.090

View more
  56 in total

Review 1.  Conservative initiation of antimicrobial treatment in ICU patients with suspected ICU-acquired infection: more haste less speed.

Authors:  Tjasa Hranjec; Robert G Sawyer
Journal:  Curr Opin Crit Care       Date:  2013-10       Impact factor: 3.687

2.  Circulating biomarkers may be unable to detect infection at the early phase of sepsis in ICU patients: the CAPTAIN prospective multicenter cohort study.

Authors:  Marianna Parlato; François Philippart; Alexandra Rouquette; Virginie Moucadel; Virginie Puchois; Sophie Blein; Jean-Pierre Bedos; Jean-Luc Diehl; Olfa Hamzaoui; Djillali Annane; Didier Journois; Myriam Ben Boutieb; Laurent Estève; Catherine Fitting; Jean-Marc Treluyer; Alexandre Pachot; Minou Adib-Conquy; Jean-Marc Cavaillon; Benoît Misset
Journal:  Intensive Care Med       Date:  2018-06-30       Impact factor: 17.440

Review 3.  Beyond Blood Culture and Gram Stain Analysis: A Review of Molecular Techniques for the Early Detection of Bacteremia in Surgical Patients.

Authors:  Michelle H Scerbo; Heidi B Kaplan; Anahita Dua; Douglas B Litwin; Catherine G Ambrose; Laura J Moore; Col Clinton K Murray; Charles E Wade; John B Holcomb
Journal:  Surg Infect (Larchmt)       Date:  2016-02-26       Impact factor: 2.150

Review 4.  [First-line anti-infective treatment in sepsis].

Authors:  H Burgmann
Journal:  Med Klin Intensivmed Notfmed       Date:  2014-10-26       Impact factor: 0.840

5.  Recent Anti-Microbial Exposure Is Associated with More Complications after Elective Surgery.

Authors:  Christopher A Guidry; Puja M Shah; Zachary C Dietch; Nathan R Elwood; Elizabeth D Krebs; J Hunter Mehaffey; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2018-06-08       Impact factor: 2.150

Review 6.  The intensive care medicine research agenda on septic shock.

Authors:  Anders Perner; Anthony C Gordon; Derek C Angus; Francois Lamontagne; Flavia Machado; James A Russell; Jean-Francois Timsit; John C Marshall; John Myburgh; Manu Shankar-Hari; Mervyn Singer
Journal:  Intensive Care Med       Date:  2017-05-12       Impact factor: 17.440

Review 7.  Management of infections in critically ill patients.

Authors:  Tjasa Hranjec; Robert G Sawyer
Journal:  Surg Infect (Larchmt)       Date:  2014-05-19       Impact factor: 2.150

8.  Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU.

Authors:  Matteo Bassetti; Garyphallia Poulakou; Jean-François Timsit
Journal:  Intensive Care Med       Date:  2016-04-04       Impact factor: 17.440

9.  Aggressive versus conservative initiation of antibiotics--authors' reply.

Authors:  Tjasa Hranjec; Robert G Sawyer
Journal:  Lancet Infect Dis       Date:  2013-05       Impact factor: 25.071

10.  [Bacteremia and sepsis].

Authors:  S Hagel; M W Pletz; F M Brunkhorst; H Seifert; W V Kern
Journal:  Internist (Berl)       Date:  2013-04       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.